BRIEF published on 09/12/2025 at 17:50, 1 year 1 month ago Abivax Joins CAC Mid 60 and SBF 120 Indices Euronext Paris Biotechnology Abivax SBF 120 CAC Mid 60
PRESS RELEASE published on 09/12/2025 at 17:45, 1 year 1 month ago Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Abivax to join CAC Mid 60 and SBF 120 Indices on Euronext Paris following annual review, enhancing visibility and investor base Euronext Paris Abivax SBF 120 Index Inclusion CAC Mid 60
BRIEF published on 09/08/2025 at 22:05, 1 year 1 month ago Abivax Reports First Half 2025 Financial Performance Financial Results Research And Development Convertible Notes Public Offering Cash Reserves
PRESS RELEASE published on 09/08/2025 at 22:00, 1 year 1 month ago Abivax Presents First Half 2025 Financial Results Abivax presents first half 2025 financial results, revealing operating loss increase and net loss for the period, also updates on clinical programs and public offering Financial Results Abivax Public Offering Clinical Programs Operating Loss
BRIEF published on 09/02/2025 at 11:00, 1 year 1 month ago JP Morgan Chase & Co. Crosses Threshold at ABIVAX Voting Rights Capital Abivax Threshold Crossing JP Morgan
BRIEF published on 08/13/2025 at 18:05, 1 year 2 months ago ABIVAX: Update on capital and voting rights Euronext Paris Share Capital Voting Rights AMF Abivax
BRIEF published on 08/13/2025 at 18:05, 1 year 2 months ago ABIVAX: Share and voting rights data as of July 31, 2025 Euronext Paris Voting Rights Biotechnology Actions AMF Regulations
BRIEF published on 07/28/2025 at 22:20, 1 year 3 months ago Abivax Completes $747.5 Million Public Offering Biotechnology Abivax Ulcerative Colitis Nasdaq Public Offer
PRESS RELEASE published on 07/28/2025 at 22:15, 1 year 3 months ago Abivax Announces Closing of $747.5 Million Public Offering Abivax announces closing of $747.5 million public offering, enabling financing into Q4 2027 and reaching planned milestones for Ulcerative Colitis. ADSs listed on Euronext Paris and Nasdaq Global Market Abivax Ulcerative Colitis Nasdaq Finance Public Offering
BRIEF published on 07/25/2025 at 08:05, 1 year 3 months ago Abivax Raises $747.5M Through ADS Offering Biotechnology Abivax Nasdaq Capital Increase ADS Offering
Published on 10/30/2026 at 23:35, 2 days 6 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 6 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 11 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 14 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 19 hours 31 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 1 day 1 hour ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 13 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 7 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 7 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 12 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 18 hours ago Capital increase through exercise of subscription rights
